IPSEN Net Cash Flow 2016-2024 | IPSEY

IPSEN net cash flow for the twelve months ending December 31, 2024 was $-0.974B, a 209.28% decline year-over-year.

  • IPSEN annual net cash flow for 2024 was $0.171B, a 124.47% decline from 2023.
  • IPSEN annual net cash flow for 2023 was $-0.699B, a 286.19% decline from 2022.
  • IPSEN annual net cash flow for 2022 was $0.376B, a 87.25% increase from 2021.

IPSEN Net Cash Flow 2016-2024 | IPSEY

  • IPSEN annual net cash flow for 2024 was $0.171B, a 124.47% decline from 2023.
  • IPSEN annual net cash flow for 2023 was $-0.699B, a 286.19% decline from 2022.
  • IPSEN annual net cash flow for 2022 was $0.376B, a 87.25% increase from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72.3B
Zoetis (ZTS)$68.6B
Takeda Pharmaceutical (TAK)$47.6B
Daiichi Sankyo, - (DSNKY)$46.4B
BeOne Medicines - (ONC)$32.7B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$18.1B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.8B
United Therapeutics (UTHR)$13.9B
Neurocrine Biosciences (NBIX)$13.8B
Orion OYJ (ORINY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.7B
Eisai (ESAIY)$9.1B
Corcept Therapeutics (CORT)$7.3B
Stevanato Group S.p.A (STVN)$7.1B
Ionis Pharmaceuticals (IONS)$6.8B
Grifols, S.A (GRFS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
Hypermarcas (HYPMY)$2.8B
Procaps Group, S.A (PROCF)$2.8B
NewAmsterdam Pharma (NAMS)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.2B
Dyne Therapeutics (DYN)$2B